成人实体器官移植后糖尿病管理专家共识  

Expert consensus on diabetes mellitus after solid organ transplantation in adults

作　　者：中国康复医学会器官移植康复专业委员会 毕艳[2] 鹿斌 Organ Transplantation and Rehabilitation Committee of Chinese Medical Association of Rehabilitation;Bi Yan;Lu Bin(不详;Department of Endocrinology,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210008,China;Department of Endocrinology,Huashan Hospital,Affiliated to Fudan University,Shanghai 200040,China)

机构地区：[1]不详 [2]南京大学医学院附属鼓楼医院内分泌科,南京210008 [3]复旦大学附属华山医院内分泌科

出　　处：《器官移植》2023年第5期623-642,共20页Organ Transplantation

摘　　要：移植后糖尿病(PTDM)是成人实体器官移植(SOT)后常见的内分泌代谢紊乱疾病,累及10%~40%的受者,严重威胁受者生存质量与长期存活。为进一步规范PTDM的诊治,相关专家依据国内外成人PTDM的研究进展并结合我国实际情况,对PTDM的流行病学、危险因素与发病机制、筛查与诊断、治疗、预防、心血管危险因素管理以及微血管并发症筛查等方面达成一致意见,提出指导建议。旨在规范化综合管理PTDM,以提高SOT受者的生存质量与长期存活。Post-transplant diabetes mellitus(PTDM)is a common endocrine and metabolic disorder after adult solid organ transplant(SOT),affecting 10%to 40%of recipients.PTDM has been associated with increased mortality,heightened risk of infections,graft-related complications and cardiovascular diseases,all of which seriously threaten the quality of life and long-term survival of recipients.According to recent studies and the domestic healthcare system,this consensus provides a comprehensive overview of the epidemiology,risk factors,pathogenesis,screening and diagnosis,treatments,prevention strategies,cardiovascular risk factor management and microvascular complications associated with PTDM,in order to further standardize the diagnosis and treatment of PTDM.The objective is to standardize the comprehensive management of PTDM with the aim of enhancing the long-term quality of life and clinical outcomes for SOT recipients.

关 键 词：移植后糖尿病 实体器官移植 免疫抑制剂 降糖药物 

分 类 号：R617[医药卫生—外科学] R587.1[医药卫生—临床医学]